Direct Answer
Amgen Inc. went public in 1983 on the Nasdaq Stock Market under the ticker symbol AMGN at an initial price of approximately $0.77 per share on a split-adjusted basis. The company completed five 2-for-1 stock splits between 1987 and 2000, resulting in a cumulative split factor of 32x. Amgen initiated its dividend in 2011, having previously returned cash exclusively through share repurchases, and has increased the dividend every year since. Amgen was added to the Dow Jones Industrial Average on August 31, 2020, replacing Pfizer, and became the first pharmaceutical or biotechnology company from the Nasdaq to join the Dow.
The 1983 IPO
Amgen Inc. went public in 1983 on the Nasdaq Stock Market under the ticker symbol AMGN. The company was among the earliest biotechnology firms to list publicly, at a time when the industry had not yet produced a commercial drug. Amgen's SEC CIK number is 0000902152. The IPO price was approximately $0.77 per share on a split-adjusted basis, accounting for the five 2-for-1 splits that occurred between 1987 and 2000.
At the time of its IPO, Amgen was a small research-stage company with a pipeline of potential biologics, operating in a sector that did not yet have an established commercial track record. The listing on Nasdaq rather than the New York Stock Exchange was common for technology and biotechnology companies at the time, and Amgen has remained on Nasdaq throughout its history. This Nasdaq listing made its eventual addition to the Dow Jones Industrial Average historically notable, as most Dow components have traditionally been NYSE-listed companies.
| IPO Detail | Value |
|---|---|
| IPO Year | 1983 |
| Exchange | Nasdaq Stock Market |
| Ticker | AMGN |
| SEC CIK | 0000902152 |
| IPO Price (split-adjusted) | approximately $0.77 per share |
| Exchange category | Technology and biotechnology exchange; most Dow components are NYSE-listed |
Stock split history
Amgen completed five stock splits between 1987 and 2000, all structured as 2-for-1 splits. Each split doubled the number of shares outstanding while halving the price per share. The cumulative split factor across all five splits is 32x (2 raised to the fifth power), meaning that one share held from before the first split became 32 shares after the final split. Amgen has not split its stock since June 2000.
| Split Date | Split Ratio | Cumulative Factor After Split |
|---|---|---|
| July 28, 1987 | 2-for-1 | 2x |
| December 9, 1991 | 2-for-1 | 4x |
| December 20, 1993 | 2-for-1 | 8x |
| March 10, 1999 | 2-for-1 | 16x |
| June 29, 2000 | 2-for-1 | 32x |
The 1987 and 1991 splits coincided with the commercial launch and rapid revenue growth of Epogen (epoetin alfa), Amgen's first major drug, which transformed the company from a research-stage organization into a profitable commercial enterprise. The 1999 and 2000 splits occurred during the late 1990s biotechnology boom, when Amgen's share price had risen substantially on the back of strong Epogen and Neupogen revenues combined with broad market enthusiasm for biotechnology. Since the 2000 split, Amgen's share price rise has not prompted an additional split.
Key price history milestones
Amgen's share price history reflects the company's transition from a research-stage startup to a large-cap pharmaceutical anchor, including periods of rapid appreciation during drug launches, sector downturns, regulatory controversies, and acquisition-driven restructuring.
| Period | Approximate Price Range | Key Driver |
|---|---|---|
| 1983 IPO | approximately $0.77 (split-adjusted) | Research-stage biotech listing |
| 1989 to 1991 | Rapid appreciation | Epogen commercial launch; revenue surged |
| Late 1990s to 2000 | Parabolic; approximately $100 in 1999 to 2000 | Biotechnology boom; strong product revenues |
| 2000 to 2002 | Fell from approximately $90 to approximately $30 | Biotechnology sector bubble burst |
| 2007 to 2012 | Range-bound with pressure | ESA controversy; Medicare restricted Aranesp and Epogen sales |
| 2013 to 2015 | From approximately $80 to approximately $180 | New drug approvals: Prolia, Enbrel growth, Kyprolis |
| 2015 to 2019 | Approximately $140 to $240 | Legacy product headwinds offset by new product growth |
| 2020 to 2021 | Approximately $230 to $280 | Dow addition August 2020; defensive healthcare positioning during COVID |
| 2022 | Reached approximately $330 (all-time high) | Broad market re-rating of established pharmaceutical names |
| 2022 to 2024 | Approximately $250 to $280 | Horizon Therapeutics acquisition integration; debt repayment period |
| End of 2024 | Approximately $275 | Post-acquisition consolidation; MariTide obesity data anticipated as re-rating catalyst |
The 2022 all-time high of approximately $330 was followed by a period of range-bound trading as the company integrated Horizon Therapeutics, a large acquisition that added the rare disease drug Tepezza to Amgen's portfolio but also substantially increased Amgen's debt load. The company suspended its share buyback program during the integration period to prioritize debt repayment, which removed a historically significant source of per-share earnings support.
Dow Jones Industrial Average membership
Amgen was added to the Dow Jones Industrial Average on August 31, 2020, replacing Pfizer. The addition was historically notable for two reasons: Amgen became the first pharmaceutical or biotechnology company from the Nasdaq exchange to join the Dow, and its inclusion was driven partly by Pfizer's declining share price, which had fallen so low that it contributed very little movement to the price-weighted index.
The Dow Jones Industrial Average is a price-weighted index, meaning that a stock with a higher share price exerts a greater influence on the index level per point of movement. When Pfizer's share price dropped substantially relative to other Dow components, its mathematical contribution to daily index moves became negligible. Amgen's higher share price at the time of inclusion restored more meaningful pharmaceutical or healthcare representation in the index on a price-weighted basis.
Most Dow components have historically been listed on the New York Stock Exchange. Amgen's inclusion from Nasdaq reflects the growing representation of technology-adjacent companies within the traditionally industrial index, though Amgen itself operates as a biotechnology company rather than a technology firm.
| Dow Membership Detail | Value |
|---|---|
| Date added to Dow | August 31, 2020 |
| Company replaced | Pfizer |
| Exchange | Nasdaq (notable; most Dow components are NYSE-listed) |
| Sector significance | First pharmaceutical or biotechnology company from Nasdaq to join the Dow |
| Reason for Pfizer replacement | Pfizer's share price had fallen so low its price-weighted influence on the Dow was minimal |
Dividend history
Amgen initiated its first dividend in 2011. This was a meaningful policy shift because the company had previously returned cash to shareholders exclusively through share repurchases. The 2011 dividend initiation signaled that Amgen had reached sufficient scale and cash generation to sustain both a growing dividend and a buyback program simultaneously, a combination that characterizes large established pharmaceutical companies rather than growth-stage biotechnology firms.
Amgen has increased its dividend every year since 2011, giving it more than 13 consecutive years of dividend increases as of the end of 2024. The quarterly dividend in fiscal year 2024 was $2.38 per share, representing an annualized rate of $9.52. At a share price of approximately $275 at the end of 2024, this represented a dividend yield of approximately 3.2 to 3.5 percent.
| Dividend Event | Detail |
|---|---|
| Dividend initiated | 2011 |
| Prior capital return method | Share repurchases only (prior to 2011 dividend initiation) |
| Consecutive years of dividend increases | 13 or more (2011 through 2024) |
| FY2024 quarterly dividend | $2.38 per share ($9.52 annualized) |
| Dividend yield (end of 2024) | approximately 3.2 to 3.5 percent (at approximately $275 per share) |
| Dividend Aristocrat status | Not yet qualified; requires 25 consecutive years of increases; estimated milestone year approximately 2036 |
Amgen does not yet qualify as a Dividend Aristocrat, the S&P 500 classification that requires 25 consecutive years of dividend increases. If the company continues its current streak without interruption, it would reach that milestone around 2036. During the Horizon Therapeutics acquisition integration period, Amgen suspended share buybacks to redirect cash flow toward debt repayment. The dividend itself was not suspended or cut during this period, preserving the consecutive-increase streak.
Valuation framework (FY2024)
Amgen's valuation at the end of 2024 reflects the complexity of a large established pharmaceutical company that recently completed a major acquisition and carries an elevated debt load. Standard valuation metrics diverge significantly between GAAP and non-GAAP measures, and investors typically focus on non-GAAP earnings to assess ongoing business performance excluding acquisition-related charges.
| Valuation Metric | FY2024 Estimate |
|---|---|
| Market capitalization (end of 2024) | approximately $148 billion (at approximately $275 per share and approximately 538 million diluted shares) |
| GAAP P/E ratio | approximately 49x (depressed by Horizon acquisition-related charges) |
| Non-GAAP P/E ratio | approximately 14x (based on FY2024 non-GAAP EPS of approximately $19.78) |
| EV/EBITDA (non-GAAP basis) | approximately 14 to 15x |
| Dividend yield | approximately 3.5 percent |
GAAP versus non-GAAP earnings
The large gap between Amgen's GAAP P/E of approximately 49x and its non-GAAP P/E of approximately 14x in FY2024 primarily reflects amortization of intangible assets and other charges associated with the Horizon Therapeutics acquisition. Acquisition accounting requires that the value assigned to acquired intangibles be amortized through the income statement over time, which reduces GAAP earnings without reflecting ongoing cash generation from the acquired business. Non-GAAP figures exclude these charges and are more commonly used by analysts to compare operating performance across periods.
Discount to pharmaceutical peers
Amgen has traded at a discount to some large-cap pharmaceutical peers partly due to the Horizon integration uncertainty and the elevated debt load taken on to finance that acquisition. The buyback suspension also removed a historically important per-share earnings driver. The pipeline candidate MariTide, Amgen's obesity drug, has been identified by investors as a potential re-rating catalyst: positive clinical data and commercial potential could substantially expand the addressable market Amgen competes in, given the recent rapid growth of the GLP-1 obesity drug category established by Novo Nordisk and Eli Lilly.
Dividend yield context
A dividend yield of approximately 3.5 percent is high relative to most large-cap pharmaceutical peers and well above the broader S&P 500 yield. The yield reflects Amgen's relatively modest share price appreciation in recent years rather than outsized dividend growth relative to peer companies. Whether the yield represents attractive value depends on investor assessment of the pipeline, debt reduction pace, and whether MariTide data will justify a meaningful re-rating of the shares.
Frequently Asked Questions
When did Amgen go public and on which exchange?
Amgen went public in 1983 on the Nasdaq Stock Market under the ticker symbol AMGN, at an initial price of approximately $0.77 per share on a split-adjusted basis. Amgen was one of the earliest biotechnology companies to go public and listed on Nasdaq, where it has remained. It was notably the first pharmaceutical or biotechnology company from Nasdaq to be added to the Dow Jones Industrial Average, which it joined in August 2020.
How many times has Amgen split its stock?
Amgen has completed five stock splits since its 1983 IPO, all of them 2-for-1. The splits occurred on July 28, 1987; December 9, 1991; December 20, 1993; March 10, 1999; and June 29, 2000. The cumulative split factor is 32x, meaning one share held continuously from before the first split became 32 shares after all five splits. Amgen has not split its stock since 2000.
When did Amgen join the Dow Jones Industrial Average?
Amgen was added to the Dow Jones Industrial Average on August 31, 2020, replacing Pfizer. Amgen was notable as the first pharmaceutical or biotechnology company from the Nasdaq exchange to join the Dow, as most Dow components are listed on the New York Stock Exchange. Pfizer's share price had fallen so low that it was barely influencing the price-weighted index, and Amgen's higher share price made it a more meaningful contributor.
Does Amgen pay a dividend and when did it start?
Yes, Amgen pays a dividend. The company initiated its first dividend in 2011, which was notable because Amgen had previously returned cash to shareholders exclusively through share buybacks. Amgen has increased its dividend every year since 2011, giving it more than 13 consecutive years of increases as of 2024. The quarterly dividend in FY2024 was $2.38 per share, representing an annualized rate of $9.52. At a share price of approximately $275 at the end of 2024, this yielded roughly 3.2 to 3.5 percent. Amgen does not yet qualify as a Dividend Aristocrat, which requires 25 consecutive years of increases; it would reach that milestone around 2036.